业务策略
实践既定战略,创造最大价值

业务模式

我们的目标是促进范围广泛的早期阶段创新治疗及诊断方案的研发和改进。最终通过再授权及商品化各项临床成果,创造价值和收入,从而进一步扩充我们的正发展项目之组合和促进业务的可持续增长。

业务策略

多元医疗领域发展

我们正研发适用于不同疾病/治疗的药品及仪器候选产品。我们相信,通过分散研究资源,能有夜提高我们任何一个旗下项目进入临床研究阶段的成功机会,并因此提升我们的企业价值。截至2017年12月31日,我们在脑神经、传染病、胃肠病、肿瘤、手术机器人和自然健康等领域取得11项专利技术的授权。

严格筛选具潜力产品,
有效扩充研发项目组合

我们严格挑选具卓越科学素质的创新产品作为研发对象,并会审视它们的市场潜力和需求规模,例如该产品能否满足目前未被满足的医疗需求。为此,知临集团旗下的Aptorum Therapeutics Limited 成立了科技评估委员会,帮助我们评估筛选项目和为未来的收购或争取获得专利授权的对象提供科学观点。我们将继续寻找适用于罕见疾病(例如:罕见的癌症)和未被满足之医疗需求的研发对象,并确保它们有强大的临床前及早期临床研究数据和商业价值。

與頂尖學術機構和委託研究機構合作

我们相信,通过与顶尖学术机构和委托研究机构合作,是我们在建立和扩充产品组合的高成本效益的重要战略。我们与全球多间顶尖学术机构建立了良好关系,并会继续强化我们之间的合作,例如以赞助形式,向大学主要研究人员提供资源,在与我们项目公司相关的专业范畴进行深入研究,我们则能拥有获得独家专利的优先权。另外,我们也与药厂签订协议,以委托研究机构的形式,协助我们推行研究项目的进程。

扩充自家制药开发中心

我们相信,由APD负责营运的研发中心与其他项目公司的科学家之间的紧密合作,能提升研发项目的临床发展和商业潜力。另外,APD将寻求外部制药公司或委托研究机构进行部分临床前或临床阶段的发展,以协助旗下项目公司的研发进程。

借力管理层的专业知识、
经验和商业网络

管理层的专业知识和经验,加上他们丰富的学术和商业网络资源,将带领知临集团成为推动医疗创新迈向临床研究和在全球主要市场推出上市的理想平台。知临集团的管理层团队拥有丰富的环球经验,在医疗行政和在医药产品的开发、并购、发展、注册及全球上市等方面均有丰厚成就;。我们也会利用管理层在银行业和金融业的经验,强化自身的运营能力,为旗下项目打造最高效的财务方案。

策略性立足香港,
贯通庞大中国市场

中国是全球第二大的保健市场,我们计划将旗下产品在中国市场营销,是我们的增长策略的重要一环。2017年10月,中国政府宣布将接受境外临床试验数据以加速内地新药的审批程序,为海外制药公司带来庞大的潜在增长动力。我们相信,香港作为中国的特别行政区,立足此地将赋予我们获取中国食品药品监督管理局(“CFDA”)认证和进入全球第二大医疗保健市场的独特优势。我们的重要合作伙伴,香港大学和香港中文大学均已成为CFDA认证的药物临床试验中心。

利用政府资源,推动项目发展

香港政府j密切注视本地生命科技行业发展,并提供多项支持和资助。我们将主动寻求政府的支持,以推进旗下研究项目的基础和发展。

×
使用条款

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.